News headlines about Arbutus Biopharma Corporation (NASDAQ:ABUS) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arbutus Biopharma Corporation earned a news impact score of 0.15 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.1113375956754 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have effected Accern’s scoring:

Arbutus Biopharma Corporation (NASDAQ ABUS) traded down $0.10 during mid-day trading on Friday, hitting $5.75. The stock had a trading volume of 146,452 shares, compared to its average volume of 250,955. Arbutus Biopharma Corporation has a 1 year low of $2.35 and a 1 year high of $8.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 11.03 and a quick ratio of 11.03.

A number of equities research analysts recently issued reports on ABUS shares. ValuEngine downgraded Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Zacks Investment Research raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, November 7th. Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 target price (up previously from $4.00) on shares of Arbutus Biopharma Corporation in a report on Tuesday, November 7th. JMP Securities reaffirmed an “outperform” rating and issued a $13.00 target price (up previously from $12.00) on shares of Arbutus Biopharma Corporation in a report on Wednesday, October 4th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $13.00.

TRADEMARK VIOLATION WARNING: “Arbutus Biopharma Corporation (ABUS) Receiving Somewhat Positive Press Coverage, Accern Reports” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/19/arbutus-biopharma-corporation-abus-receiving-somewhat-positive-press-coverage-accern-reports.html.

In other news, insider Michael J. Sofia sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total value of $80,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.00% of the company’s stock.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.